Doogan Declan 4/A
4/A · Biohaven Pharmaceutical Holding Co Ltd. · Filed Feb 11, 2022
Insider Transaction Report
Form 4/AAmended
Doogan Declan
Director
Transactions
- Sale
Common Shares
2020-06-11$64.42/sh−11,706$754,125→ 859,335 total(indirect: By Trust) - Sale
Common Shares
2020-06-11$64.71/sh−13,333$862,748→ 360,580 total - Sale
Common Shares
2020-06-12$65.55/sh−12,580$824,635→ 792,669 total(indirect: By Trust) - Sale
Common Shares
2020-06-12$66.01/sh−13,334$880,115→ 347,246 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.31 - $64.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F2]This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 12, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.54 - $65.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 - $65.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.79 - $66.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.